ReviewJournal of scleroderma and related disorders2020
Antisynthetase syndrome: A distinct disease spectrum.
Review in Journal of scleroderma and related disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Systematic Review of Kidney Involvement in Antisynthetase Syndrome.Kidney international reports · 2026Article
- Clinical characteristics, organ damage and survival in idiopathic inflammatory myopathies: a long-term retrospective cohort study.Rheumatology international · 2026Article
- Evaluating the value of superoxide dismutase in anti-synthetase syndrome associated with interstitial lung disease.Clinical rheumatology · 2026Article
- Disparate periphery and lung immune microenvironments induced monocyte-macrophage activation as a key factor in anti-synthetase syndrome-associated interstitial lung disease.Respiratory research · 2026Article
- Review
- Risk Factors for Recurrence of the Anti-Synthetase Syndrome Related Interstitial Lung Disease.Immunity, inflammation and disease · 2026Article
- Diffuse Alveolar Haemorrhage as a Rare Pulmonary Manifestation of Antisynthetase Syndrome: A Case Series.Journal of clinical medicine · 2026Article
- Hypereosinophilia Associated With Antisynthetase Syndrome With Anti-Ro52/PL12 Co-Positivity: An Unusual Presentation.Clinical case reports · 2026Article
- Regional differences in clinical manifestations of antisynthetase syndrome: a comparison between Asian and European cohorts.Arthritis research & therapy · 2026Article
- A Rare Case Report of Antisynthetase Syndrome With Progressive Myopathy and Interstitial Lung Disease in a 38-Year-Old Male.Clinical case reports · 2026Article
- Cluster analysis and risk prediction model construction for antisynthase syndrome-associated interstitial lung disease based on clinical, imaging, and antibody characteristics.Frontiers in medicine · 2026Article
- Postpartum-onset anti-PM/Scl-positive dermatomyositis-systemic sclerosis overlap syndrome with reversible interstitial lung disease: a case report.Frontiers in medicine · 2026Article
- Antisynthetase Syndrome With Classic Features and Anti‑PL‑7 Positivity: A Rare Immunologic Variant.Cureus · 2025Article
- Antisynthetase Syndrome Masquerading As Psoriasis and Psoriatic Arthritis: A Case Report.Cureus · 2025Article
- Advances in the Regulation by Immune Cells of Skeletal Myositis Outcomes.Aging and disease · 2025Review
- Clinical Characteristics of Anti-Synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- Prevalence of Anti-Synthetase Syndrome in Patients of Interstitial Lung Disease with Connective Tissue Diseases and Autoimmune Features: A Cross-Sectional Study.Mediterranean journal of rheumatology · 2025Article
- Epidemiology of Antisynthetase Syndrome and Risk of Malignancy in a Population-Based Cohort (1998-2019).The Journal of rheumatology · 2025Article
- Hidden in Plain Sight: Antisynthetase Syndrome Masquerading As Acute Coronary Syndrome and Heart Failure.Cureus · 2024Article
- Myositis-Associated Interstitial Lung Disease: The Experience of a Tertiary Center.Journal of clinical medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery of novel autoantibodies related to idiopathic inflammatory myopathies (collectively referred to as myositis) has not only advanced our understanding of the clinical, serological, and pathological correlation in the disease spectrum but also played a role in guiding management and prognosis. One group of the myositis-specific autoantibodies is anti-aminoacyl-tRNA synthetase (anti-ARS or anti-synthetase) which defines a syndrome with predominant interstitial lung disease, arthritis, and myositis. Autoantibodies to eight aminoacyl-tRNA synthetases have been identified with anti-Jo1 the most common in all of idiopathic inflammatory myopathies. Disease presentation and prognosis vary depending on which anti-aminoacyl-tRNA synthetase antibody is present. In this review, we will discuss the clinical characteristics, overlap features with other autoimmune diseases, prognostic factors, and management of the antisynthetase syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.